Paper39217384
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension.
Lee HY and 12 others. Clin Hypertens, 2024. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension. Papers, record 39217384. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39217384
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References132
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36788612 | The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. | Clin Hypertens | 2023 | https://conductscience.org/library/papers/36788612 | PubMed |
| 2 | 37356031 | Addendum. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S41-S48. | Diabetes Care | 2023 | https://conductscience.org/library/papers/37356031 | PubMed |
| 3 | 27295427 | Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27295427 | PubMed |
| 4 | 26630143 | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26630143 | PubMed |
| 5 | 33470881 | Direct medical costs of obesity in the United States and the most populous states. | J Manag Care Spec Pharm | 2021 | https://conductscience.org/library/papers/33470881 | PubMed |
| 6 | 31924562 | The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. | Lancet Diabetes Endocrinol | 2020 | https://conductscience.org/library/papers/31924562 | PubMed |
| 7 | 33292736 | Metabolomics profiling in hypertension and blood pressure regulation: a review. | Clin Hypertens | 2020 | https://conductscience.org/library/papers/33292736 | PubMed |
| 8 | 24796231 | Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). | Hepatol Res | 2015 | https://conductscience.org/library/papers/24796231 | PubMed |
| 9 | 37356073 | Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis. | Diabetes Metab Res Rev | 2023 | https://conductscience.org/library/papers/37356073 | PubMed |
| 10 | 36977782 | Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. | Nat Rev Cardiol | 2023 | https://conductscience.org/library/papers/36977782 | PubMed |
| 11 | 16275870 | Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. | Circulation | 2005 | https://conductscience.org/library/papers/16275870 | PubMed |
| 12 | 34450083 | Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. | Lancet | 2021 | https://conductscience.org/library/papers/34450083 | PubMed |
| 13 | 6877358 | Exon duplication and divergence in the human preproglucagon gene. | Nature | 1983 | https://conductscience.org/library/papers/6877358 | PubMed |
| 14 | 37524445 | Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses. | Gut | 2023 | https://conductscience.org/library/papers/37524445 | PubMed |
| 15 | 33685583 | Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. | Elife | 2021 | https://conductscience.org/library/papers/33685583 | PubMed |
| 16 | 16936160 | Effect of weight loss with lifestyle intervention on risk of diabetes. | Diabetes Care | 2006 | https://conductscience.org/library/papers/16936160 | PubMed |
| 17 | 33068776 | GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. | Mol Metab | 2021 | https://conductscience.org/library/papers/33068776 | PubMed |
| 18 | 37122032 | Suboptimal control status of young hypertensive population. | Clin Hypertens | 2023 | https://conductscience.org/library/papers/37122032 | PubMed |
| 19 | 35624390 | Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. | Curr Atheroscler Rep | 2022 | https://conductscience.org/library/papers/35624390 | PubMed |
| 20 | 26803771 | GLP-1 Agonists and Blood Pressure: A Review of the Evidence. | Curr Hypertens Rep | 2016 | https://conductscience.org/library/papers/26803771 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42783463 | Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42783463 | PubMed |
| 42583966 | Systemic pathways linking subcutaneous therapies to gastrointestinal adverse effects: A Narrative review of mechanisms and mitigation strategies. | Indian J Pharmacol | 2026 | https://conductscience.org/library/papers/42583966 | PubMed |
| 42429894 | Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies. | Am J Cardiovasc Drugs | 2026 | https://conductscience.org/library/papers/42429894 | PubMed |
| 42243292 | Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes. | Hypertens Res | 2026 | https://conductscience.org/library/papers/42243292 | PubMed |
| 42056284 | Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG). | J Hum Hypertens | 2026 | https://conductscience.org/library/papers/42056284 | PubMed |
| 41178712 | GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. | J Clin Invest | 2025 | https://conductscience.org/library/papers/41178712 | PubMed |
| 40497273 | Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release. | J Hand Surg Glob Online | 2025 | https://conductscience.org/library/papers/40497273 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39217384
GET https://conductscience.org/api/papers/v1/39217384/references?page=2